← Back to Home

Personalized Cancer Vaccines Move to the Next Stage: Moderna and Merck to Present Phase 3 Melanoma Details

The phase 3 trial has been announced to have met its endpoints; the real test is how large the benefit is and how long it lasts. The October 24 data presentation will also provide important evidence to inform the two companies’ plans to target earlier-stage cancers.

By SURL BioNews

How to reduce the risk of cancer returning after tumor removal remains a challenge in postoperative treatment. Moderna and Merck have announced that their jointly developed personalized mRNA cancer vaccine, intismeran autogene, met its endpoints in a phase 3 melanoma trial. Development now moves from asking whether it works to a more detailed examination: how much patients benefit, and whether the strategy can extend to other cancers.

According to the agenda released by Moderna, results from the INTerpath-001 trial are scheduled to be presented by lead investigator Georgina Long on October 24 at a Presidential Symposium during the European Society for Medical Oncology (ESMO) Congress. The presentation follows the preliminary results announced by the two companies in August; it is not another announcement of the trial’s success. As of October 19, the company announcements reviewed had not provided the phase 3 trial’s hazard ratios, absolute benefits, or complete adverse event data.

INTerpath-001 enrolled 1,137 patients with completely resected stage IIB to IV cutaneous melanoma who were at higher risk of recurrence. It compared the vaccine in combination with the anti-PD-1 drug pembrolizumab (Keytruda) against pembrolizumab alone. The two companies said a prespecified interim analysis showed that the combination improved the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. Follow-up continues for outcomes including overall survival.

The vaccine is made based on the mutation profile of each patient’s tumor, with the aim of guiding the immune system to recognize cancer cells. Combining it with pembrolizumab is intended to provide recognition cues while blocking some of the signals that suppress the immune response. This is a personalized strategy for cancer treatment, and evidence of its efficacy must be understood within the context of the specific cancer type, disease stage, and treatment combination.

Plans for the next steps are becoming clearer. According to STAT’s October 15 summit coverage, Moderna President Stephen Hoge and Merck’s head of research and development, Dean Li, discussed preparations to seek approval, as well as postoperative treatment trials in lung, kidney, and bladder cancers. They also discussed the possibility of treating earlier-stage disease and their hope of using immune response data accumulated in clinical trials to improve the algorithm for selecting tumor neoantigens. Each of these directions still requires clinical validation.

This year’s ESMO Congress will also feature results from a phase 1 pancreatic cancer trial and the design of INTerpath-014, a phase 3 trial in early-stage lung cancer. These represent different levels of progress: the former provides preliminary human evidence, while the latter describes how the therapy will be tested. They cannot be regarded as proof of efficacy across cancer types. Although no new safety signals emerged in the melanoma trial, complete data are still needed to assess the treatment burden. For patients, the most important questions ahead are how much the risk of recurrence is reduced, how long the effect lasts, and whether it ultimately translates into longer life.

References

  1. Stocktwits
  2. Moderna via ACCESS Newswire / FinancialContent
  3. Merck
  4. STAT